For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and ...

Halozyme Therapeutics, Inc.'s subcu drug delivery business, driven by ENHANZE technology, shows strong revenue growth with significant collaborations, but faces potential challenges post-2030 due ...

Analyst Jason Butler of JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report), retaining the price target of $73.00.Stay ...

Contacts: Tram BuiVP, Investor Relations and Corporate [email protected] Samantha [email protected] The following tables reconcile ...

Halozyme Therapeutics, Inc. (HALO) stock price is 55.83 and Halozyme Therapeutics, Inc. (HALO) 10-day simple moving average is 55.30. Halozyme Therapeutics, Inc. (HALO) stock price is 55.83 and ...

TD Cowen analyst Brendan Smith reiterated a Buy rating on Halozyme (HALO – Research Report) today and set a price target of $77.00. Discover outperforming stocks and invest smarter with Top ...

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto ...

San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor ...

SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full year 2024 financial guidance ...